Despite the headwinds faced by the office sector and gateway markets, Boston's new-supply pipeline for life sciences-based real estate remains robust, according to CommercialEdge's business manager, Doug Ressler.
"Thanks in part to breakthroughs of mRNA and CRISPR technologies, billions of dollars of funding— both private and public—have been flowing into the life science sectors in recent years," Ressler tells GlobeSt.com.
"Investors are paying top dollar for lab space, and developers are rushing to bring more to market. While there has been some concern in recent months that rising interest rates and general economic weakness could cause a slowdown in the sector, it has not yet manifested in the sales and supply data."
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
